Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Surg Oncol Clin N Am. 2020 Oct;29(4):555-569. doi: 10.1016/j.soc.2020.06.009. Epub 2020 Jul 29.
Immunotherapy, targeted therapy, and adoptive T-cell therapy have been revolutionary advancements in cancer research. Some of these therapies have become the standard of care for lung cancer and replaced older treatment algorithms; some continue to be studied in clinical trials. This article discusses the current state of novel treatment options for non-small cell lung cancer patients with metastatic and locoregional disease, with focus on immunotherapy, targeted therapy, and adoptive T-cell therapy.
免疫疗法、靶向治疗和过继性 T 细胞疗法是癌症研究领域的革命性进展。其中一些疗法已成为肺癌的标准治疗方法，取代了旧的治疗方案；一些仍在临床试验中进行研究。本文讨论了转移性和局部区域性疾病非小细胞肺癌患者的新型治疗选择的现状，重点关注免疫疗法、靶向治疗和过继性 T 细胞疗法。
